Literature DB >> 11245279

Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors.

V K Puduvalli1, R Sawaya.   

Abstract

The poor prognosis of patients with malignant brain tumors in spite of aggressive multimodality therapy has led to the search for novel therapeutic strategies. Among the targets for such treatment approaches, tumor angiogenesis has captured the attention of not only the medical field but also of the lay public because of its conceptual departure from traditional methods of cancer therapy. Angiogenesis and vascular proliferation are particularly important in the growth and progression of malignant gliomas and are used as indicators of the degree of malignancy. Recent studies have helped us gain a better understanding of the molecular mediators of this process. It is now evident that after the initial formation of malignancy the continued growth of a glioma is critically dependent on its angiogenic potential. Hence, several approaches to control angiogenesis are being developed and tested. In the present review, we examine some of these approaches from a therapeutic perspective and summarize the findings from early human trials of such agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11245279     DOI: 10.1023/a:1006469830739

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  92 in total

Review 1.  Angiogenesis in brain tumors; pathobiological and clinical aspects.

Authors:  P Wesseling; D J Ruiter; P C Burger
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 2.  Development of angiogenesis inhibitors for cancer therapy.

Authors:  S G Eckhardt; J M Pluda
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

4.  Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing.

Authors:  N N Nissen; P J Polverini; A E Koch; M V Volin; R L Gamelli; L A DiPietro
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

5.  Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody.

Authors:  J R Sheu; M H Yen; Y C Kan; W C Hung; P T Chang; H N Luk
Journal:  Biochim Biophys Acta       Date:  1997-10-20

6.  The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells.

Authors:  A D Heyns; A Eldor; I Vlodavsky; N Kaiser; R Fridman; A Panet
Journal:  Exp Cell Res       Date:  1985-12       Impact factor: 3.905

7.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors:  K H Plate; G Breier; H A Weich; W Risau
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

8.  Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo.

Authors:  S Mohanam; S W Wang; A Rayford; M Yamamoto; R Sawaya; M Nakajima; L A Liotta; G L Nicolson; W G Stetler-Stevenson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1995-01       Impact factor: 5.150

9.  Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand-induced binding site on beta 3 subunit.

Authors:  D Juliano; Y Wang; C Marcinkiewicz; L A Rosenthal; G J Stewart; S Niewiarowski
Journal:  Exp Cell Res       Date:  1996-05-25       Impact factor: 3.905

Review 10.  Role of integrins in cancer: survey of expression patterns.

Authors:  G J Mizejewski
Journal:  Proc Soc Exp Biol Med       Date:  1999-11
View more
  26 in total

Review 1.  Gene therapy for glioblastoma: future perspective for delivery systems and molecular targets.

Authors:  A Shir; A Levitzki
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

2.  Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.

Authors:  Dongxiao Yao; Hongyang Zhao; Fangcheng Zhang; Jian Chen; Xiaobing Jiang; Xianli Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

Review 3.  Update on brain tumor imaging: from anatomy to physiology.

Authors:  S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

4.  S100A13, a new marker of angiogenesis in human astrocytic gliomas.

Authors:  M Landriscina; G Schinzari; G Di Leonardo; M Quirino; A Cassano; E D'Argento; L Lauriola; M Scerrati; I Prudovsky; C Barone
Journal:  J Neurooncol       Date:  2006-06-14       Impact factor: 4.130

5.  Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma.

Authors:  Yang Liu; Yang Zhou; Xiu-Shi Zhang; Bao-Zhong Shen
Journal:  Oncol Lett       Date:  2011-08-17       Impact factor: 2.967

6.  Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

Authors:  James L Frazier; Paul P Wang; Daniel Case; Betty M Tyler; Gustavo Pradilla; Jon D Weingart; Henry Brem
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

7.  Spatial expression of VEGF-A in human glioma.

Authors:  Mikael Johansson; Thomas Brännström; A Tommy Bergenheim; Roger Henriksson
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

8.  The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.

Authors:  John J Haddad
Journal:  Saudi Pharm J       Date:  2011-09-23       Impact factor: 4.330

Review 9.  Targeting angiogenesis in pancreatic cancer: rationale and pitfalls.

Authors:  Chery Whipple; Murray Korc
Journal:  Langenbecks Arch Surg       Date:  2008-01-22       Impact factor: 3.445

10.  Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.

Authors:  Oszkar Szentirmai; Cheryl H Baker; Szofia S Bullain; Ning Lin; Masaya Takahashi; Judah Folkman; Richard C Mulligan; Bob S Carter
Journal:  J Neurosurg       Date:  2008-05       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.